Redhill Biopharma Ltd. (NASDAQ:RDHL)‘s stock had its “buy” rating restated by equities researchers at Roth Capital in a report issued on Wednesday. They currently have a $27.00 target price on the biotechnology company’s stock. Roth Capital’s price objective would indicate a potential upside of 187.54% from the stock’s previous close.

Several other research firms also recently issued reports on RDHL. HC Wainwright raised their price target on shares of Redhill Biopharma from $33.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research raised shares of Redhill Biopharma from a “sell” rating to a “hold” rating in a research note on Wednesday, September 27th. UBS AG assumed coverage on Redhill Biopharma in a report on Wednesday, September 13th. They issued a “reduce” rating for the company. Finally, FBR & Co restated a “buy” rating on shares of Redhill Biopharma in a report on Friday, June 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Redhill Biopharma has an average rating of “Hold” and an average target price of $24.44.

Shares of Redhill Biopharma (RDHL) traded up 4.8488% during midday trading on Wednesday, hitting $9.8453. The company had a trading volume of 173,254 shares. Redhill Biopharma has a one year low of $8.16 and a one year high of $14.74. The stock’s 50-day moving average price is $8.88 and its 200-day moving average price is $9.33. The stock’s market capitalization is $168.97 million.

Redhill Biopharma (NASDAQ:RDHL) last posted its earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). The business had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $0.34 million. Analysts predict that Redhill Biopharma will post ($2.36) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.watchlistnews.com/redhill-biopharma-ltd-rdhl-stock-rating-reaffirmed-by-roth-capital/1608098.html.

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new stake in Redhill Biopharma during the 1st quarter valued at approximately $101,000. Family Management Corp acquired a new position in shares of Redhill Biopharma in the 1st quarter worth approximately $163,000. Oppenheimer & Co. Inc. lifted its position in shares of Redhill Biopharma by 36.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 6,172 shares during the period. Jane Street Group LLC acquired a new position in shares of Redhill Biopharma in the 1st quarter worth approximately $276,000. Finally, D.A. Davidson & CO. lifted its position in shares of Redhill Biopharma by 10.0% in the 2nd quarter. D.A. Davidson & CO. now owns 44,000 shares of the biotechnology company’s stock worth $379,000 after purchasing an additional 4,000 shares during the period. 10.99% of the stock is owned by institutional investors and hedge funds.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.